• 7 (re)new(ed) strategic partnerships push flanders.bio forward into 2022

    11 hours ago

  • Jyseleca®▼ (Filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

    16 hours ago

  • The new Walloon company Cellaïon makes its first closing

    16 hours ago

  • Mithra announces positive top-line results from Donesta® Phase 3 studies in menopausal women

    Friday January 14th 2022

  • BioStrand secures second VLAIO research grant

    Thursday January 13th 2022

  • Biotalys and Olon enter into long-term partnership for the production of protein-based biocontrols

    Wednesday January 12th 2022

  • Biohaven enters exclusive license and research collaboration agreement with KU Leuven to advance first-in-class TRPM3 antagonists for the treatment of pain

    Wednesday January 12th 2022

  • Oxurion provides update on clinical pipeline progress

    Friday January 7th 2022

  • Your news here?

  • Ardena expands capacity to satisfy Novavax COVID vaccine demand

    Thursday January 6th 2022

  • Belgian research team uses AI to explain cell diversity in the fly brain

    Thursday January 6th 2022

  • Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis

    Thursday January 6th 2022

Strategic Partners